Robert W. Baird initiated coverage on iRhythm with a new price target
$IRTC
Medical/Dental Instruments
Health Care
Robert W. Baird initiated coverage of iRhythm with a rating of Outperform and set a new price target of $130.00
Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/2/2025 | $130.00 | Equal Weight → Overweight | Wells Fargo |
| 12/3/2024 | $86.00 | Equal Weight | Wells Fargo |
| 10/4/2024 | $78.00 | Neutral | Goldman |
| 6/20/2024 | $115.00 | Peer Perform → Outperform | Wolfe Research |
| 12/11/2023 | $110.00 | Neutral → Buy | Citigroup |
| 7/19/2023 | $130.00 | Outperform | Robert W. Baird |
| 2/7/2023 | $150.00 | Overweight | Wells Fargo |
| 11/7/2022 | Underperform → Peer Perform | Wolfe Research |
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4/A - iRhythm Technologies, Inc. (0001388658) (Issuer)
MarketNewsUpdates News Commentary NEW YORK, July 15, 2025 /PRNewswire/ -- Artificial Intelligence (AI) algorithms are revolutionizing the way retina images are analyzed for detecting conditions such as age-related macular degeneration (AMD) and diabetic retinopathy. These advanced algorithms often achieve diagnostic accuracies that equal or surpass human experts, especially in complex cases. This capability not only enhances diagnostic precision but also supports clinicians in delivering more effective treatment strategies. AI systems that analyze retina images can spot early signs of diseases like age-related macular degeneration (AMD) and diabetic retinopathy. These conditions often devel
SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O'Boyle have accepted appointments to the board of directors. Mark Rubash has served on the board since 2016, prior to the company's initial public offering, bringing decades of experience in finance, accounting, and strategy at high-growth technology companies. Ralph Snyderman, M.D., who joined the board in 2017, br
SAN FRANCISCO, June 23, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) announced the results from two large-scale real-world studies presented at the American Diabetes Association's 85th Scientific Sessions (ADA 2025). The analyses reveal that cardiac arrhythmias are common and often occur early in people with type 2 diabetes (T2D)—especially those who also have chronic kidney disease (CKD). These findings suggest a critical opportunity to enhance early detection strategies in at-risk cardiometabolic populations. The studies examined longitudinal claims data from over 30 million U.S. adults, providing new insights into how arrhythmias—often asymptomatic—cluster around
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
4 - iRhythm Technologies, Inc. (0001388658) (Issuer)
3 - iRhythm Technologies, Inc. (0001388658) (Issuer)
Wells Fargo upgraded iRhythm from Equal Weight to Overweight and set a new price target of $130.00
Wells Fargo resumed coverage of iRhythm with a rating of Equal Weight and set a new price target of $86.00
Goldman initiated coverage of iRhythm with a rating of Neutral and set a new price target of $78.00
8-K - iRhythm Technologies, Inc. (0001388658) (Filer)
144 - iRhythm Technologies, Inc. (0001388658) (Subject)
8-K - iRhythm Technologies, Inc. (0001388658) (Filer)
iRhythm is the first medical device company to join the Epic community, using Aura to drive efficiencies through EHR integrationThe collaboration will expand access to Zio service across the continuum of patient care—from cardiology to primary care to emergency departments and beyond1 SAN FRANCISCO, Feb. 29, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital healthcare company focused on creating trusted solutions that detect, predict, and prevent disease, today announced it will use Epic's Aura platform to streamline access to iRhythm's Zio long-term continuous monitoring and ambulatory mobile cardiac telemetry services ("Zio services") through improved
A seasoned leader, Sung brings deep finance, capital markets, and strategy experience across the medical device industry Aerin Medical Inc., a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, announced today that Derrick Sung has been appointed chief financial officer of the company. Sung brings over 25 years of finance, capital markets, and strategy experience across diverse roles within the medical device industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231120576987/en/Derrick Sung has been appointed chief financial officer
SAN FRANCISCO, June 06, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the appointment of Mojdeh Poul and Brian Yoor as directors to its Board effective June 1, 2023. "On behalf of the entire iRhythm team, I am thrilled to welcome Mojdeh and Brian to our Board of Directors," said Quentin Blackford, iRhythm's President and CEO. "Both bring extensive operational experience, strong financial acumen, and public company leadership across the global healthcare and medical technology sectors. We believe their proven track record of delivering
SAN FRANCISCO, May 01, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended March 31, 2025. First Quarter 2025 Financial Highlights Revenue of $158.7 million, a 20.3% increase compared to first quarter 2024Gross margin of 68.8%, a 250-basis point increase compared to first quarter 2024Unrestricted cash, cash equivalents, and marketable securities of $520.6 million as of March 31, 2025Increased fiscal year 2025 guidance for revenue and adjusted EBITDA margin Recent Operational Highlights Strong qu
SAN FRANCISCO, April 17, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2025 after the close of trading on Thursday, May 1, 2025. The company's management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the conference call on the "Quarterly Results" section of the company's investor website at investors.irhythmtech.com. About iRhythm Technologies, Inc. iRhythm is a leading di
SAN FRANCISCO, Feb. 20, 2025 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months and full year ended December 31, 2024. Fourth Quarter 2024 Financial Highlights Revenue of $164.3 million, a 24.0% increase compared to fourth quarter 2023Gross margin of 70.0%, a 410-basis point increase compared to fourth quarter 2023Net loss of $1.3 million, a $37.4 million improvement compared to fourth quarter 2023Adjusted EBITDA of $19.3 million, a $16.9 million improvement compared to fourth quarter 2023Cash, cash equ
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)
SC 13G/A - iRhythm Technologies, Inc. (0001388658) (Subject)